Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C27H36N4O2 |
Molecular Weight | 448.6003 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C2=C3C[C@@H](CCC3=C(C)C=C2)NC(=O)C4=CC=C(C=C4)N5CCOCC5
InChI
InChIKey=IHDRUIHIJWCTIY-JOCHJYFZSA-N
InChI=1S/C27H36N4O2/c1-20-3-10-26(31-13-11-29(2)12-14-31)25-19-22(6-9-24(20)25)28-27(32)21-4-7-23(8-5-21)30-15-17-33-18-16-30/h3-5,7-8,10,22H,6,9,11-19H2,1-2H3,(H,28,32)/t22-/m1/s1
Molecular Formula | C27H36N4O2 |
Molecular Weight | 448.6003 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Behavioral pharmacology of AR-A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist. | 2003 Mar |
|
Pharmacology of a novel selective 5-hydroxytryptamine1B receptor antagonist, AR-A000002. | 2004 Mar |
|
Effects of long-term administration of the 5-hydroxytryptamine1B receptor antagonist AR-A000002 to guinea pigs. | 2004 Mar |
|
In vitro characterization of AR-A000002, a novel 5-hydroxytryptamine(1B) autoreceptor antagonist. | 2004 Sep 19 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:37:00 GMT 2023
by
admin
on
Sat Dec 16 10:37:00 GMT 2023
|
Record UNII |
L3CZ2XB4ER
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID801027304
Created by
admin on Sat Dec 16 10:37:00 GMT 2023 , Edited by admin on Sat Dec 16 10:37:00 GMT 2023
|
PRIMARY | |||
|
AR-A000002
Created by
admin on Sat Dec 16 10:37:00 GMT 2023 , Edited by admin on Sat Dec 16 10:37:00 GMT 2023
|
PRIMARY | AR-A000002 is a drug which is one of the first compounds developed to act as a selective antagonist for the serotonin receptor 5-HT1B, with approximately 10x selectivity for 5-HT1B over the closely related 5-HT1D receptor. It has been shown to produce sustained increases in levels of serotonin in the brain, and has anxiolytic effects in animal studies. | ||
|
9846516
Created by
admin on Sat Dec 16 10:37:00 GMT 2023 , Edited by admin on Sat Dec 16 10:37:00 GMT 2023
|
PRIMARY | |||
|
220051-79-6
Created by
admin on Sat Dec 16 10:37:00 GMT 2023 , Edited by admin on Sat Dec 16 10:37:00 GMT 2023
|
PRIMARY | |||
|
L3CZ2XB4ER
Created by
admin on Sat Dec 16 10:37:00 GMT 2023 , Edited by admin on Sat Dec 16 10:37:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Chemical synthesis of the compound.
|
||
|
ACTIVE MOIETY |
Class: Antidepressant, Anxiolytic; Mechanism of Action: Serotonin 1B receptor antagonist; Highest Development Phase: Discontinued for Anxiety disorders and Major depressive disorder
|